BioSpace News Archive

Cytokinetics, Incorporated announced that on January 31, 2022 it granted stock options to purchase an aggregate of 200,700 shares of common stock to 15 new employees, whose employment commenced in January 2022, as a material inducement to their employment.

MEI Pharma, Inc. today announced the grant of inducement stock options for an aggregate of 588,000 shares of the company’s common stock to seven new employees.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2022.

Pfizer Inc. and BioNTech SE announced that following a request from the U.S. Food and Drug Administration the companies have initiated a rolling submission seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, in response to the urgent public health need in this population.

Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), today announced the upcoming podium presentation of the latest interim analysis from the ALIGN3D™ clinical study at the 2022 American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022.

BioLife Sciences (OTCPK: BLFE) is pleased to announce that it has finalized a definitive agreement (the “Agreement”) with Health Box LLC towards the 100% acquisition of the Arizona-based orthomolecular medicine and natural health products company.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, after the market closes.

SELLAS Life Sciences Group, Inc. announced today the completion of enrollment in the Phase 1/2 clinical trial of the Company’s lead asset, galinpepimut-S (GPS), in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®.